Literature DB >> 31690400

Immunobiologic treatments for severe asthma, atopic dermatitis, and chronic urticaria.

Sergio E Chiarella.   

Abstract

Immunobiologic agents are an important therapeutic alternative for severe asthma, atopic dermatitis, and chronic urticaria. In this article, we reviewed the most relevant studies that addressed the use of anti-immunoglobulin E (omalizumab), anti-IL-5 (mepolizumab, reslizumab, and benralizumab), and anti-IL-4/IL-13 (dupilumab) treatments for these allergic diseases. In addition, we discussed emerging immunobiologic therapies, such as tezepelumab.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31690400     DOI: 10.2500/aap.2019.40.4277

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  2 in total

1.  The continuing "1000 faces of asthma".

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2020-05-01       Impact factor: 2.587

2.  Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report.

Authors:  David N Pham
Journal:  J Med Case Rep       Date:  2021-03-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.